| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
We investigated the feasibility of converting total shoulder arthroplasty (TSA) into an outpatient procedure using ambulatory interscalene perineural ropivacaine infusion. Of the patients of the first phase (n = 8) who were required to remain hospitalized for at least 1 postoperative night, 5 met discharge criteria in the recovery room. Of the subsequent patients of the second phase (n = 6), all met discharge criteria in the recovery room after surgery, and 5 were discharged directly home. For all patients, postoperative pain was well controlled, oral opioid requirements and sleep disturbances were minimal, range-of-motion consistently reached or exceeded the surgeons expectations, and patient satisfaction was high. These results suggest that TSA may be performed on an outpatient basis using perineural local anesthetic infusion. Additional research is required to define the appropriate subset of patients and assess the incidence of complications associated with this practice before its mainstream use.
Total shoulder arthroplasty (TSA) results in severe postoperative pain that traditionally requires hospital admission to provide potent analgesia with IV opioids for both baseline pain and to enable effective rehabilitation (14). Perineural infusion or a continuous nerve block does not always require hospitalization (5), and provides site-specific analgesia with minor, if any, side effects (6,7). Portable infusion pumps have been used to improve analgesia for outpatients after mild and moderately painful ambulatory shoulder surgery (711). This pilot study was designed to evaluate the feasibility of converting TSA into an ambulatory procedure using perineural interscalene local anesthetic infusion and portable infusion pumps.
The investigation was divided into two phases: the Hospitalized phase allowed for patient discharge as early as the day after surgery, postoperative day (POD) 1, whereas the Ambulatory phase allowed for discharge home directly from the postanesthesia care unit (PACU). The Hospitalized phase was prospectively designated to conclude after 5 patients had met all discharge criteria (Table 1) both in the PACU and POD 1, and subsequently completed their infusion successfully at home. Successful infusion was defined for both phases as a patient 1) receiving acceptable analgesia as measured using a numeric rating pain scale (NRS <4; scale of 010, 0 = no pain, 10 = worst imaginable pain) throughout POD 7 (12); 2) avoiding hospital readmission; and 3) achieving at least 50% of the surgeons shoulder elevation and external rotation goals (defined below) in the PACU and on POD 3. The Ambulatory phase was designated to conclude after successful completion of 5, of a maximum of 10, patients.
Hospitalized Phase After written, informed consent, interscalene catheters (StimuCath; Arrow International, Reading, PA) were placed using a technique described previously (8). Forty milliliters of ropivacaine, 0.2%, with epinephrine, 100 µg, was injected via the catheter with gentle aspiration every 35 mL. For the surgical procedure, patients received a standardized general anesthetic without opioids. Postoperatively, a perineural bolus was administered for an NRS >3 (20 mL of ropivacaine, 0.2%, with epinephrine, 50 µg), and an electronic, portable infusion pump (CADD-Legacy PCA; Smiths Medical, St. Paul, MN) with a 600-mL reservoir of ropivacaine, 0.2%, was attached to the catheter (basal rate = 7 mL/h, bolus = 3 mL, lockout = 60 min) (13). Patients received scheduled celecoxib, 100 mg twice daily, and acetaminophen, 975 mg every 6 h. Rescue opioid and route of administration were determined by pain severity: oral oxycodone 5 mg (NRS <4), oral oxycodone 10 mg (NRS = 45), or IV morphine 24 mg (NRS >5). The patient and caretaker were given verbal and written instructions on the use of the pump and catheter along with physician telephone and pager numbers. In the PACU, both patients and their caretakers received instruction on rehabilitation exercises by a physical therapist. The primary indicator of functional outcome after TSA is range-of-motion (14). For the first 26 wk after surgery, patients undergo passive elevation and external rotation up to surgeon-defined maximums, or goals, to avoid damaging the rotator cuff (3,15). Prospectively determined discharge criteria (Table 1) were subsequently evaluated and patients discharged to the hospitals General Clinical Research Center (GCRC), and then home the following morning if they again met criteria for discharge. Patients were telephoned beginning the night of surgery, and each evening thereafter through the night after catheter removal. On POD 3, patients returned to the GCRC to have their catheter site examined, local anesthetic reservoir replenished, and undergo a rehabilitation session with a physical therapist. In the evening of POD 6, patients caretakers removed the catheters using a pair of nonsterile gloves, with a physician in telephone contact throughout.
Ambulatory Phase
Hospitalized Phase Eight patients were enrolled in this phase and had an interscalene catheter placed successfully (Table 2). One subject was erroneously included in the study (exclusion criteria: asthma), and was removed from the investigation. Five patients (63%) met all discharge criteria both in the PACU and on POD 1, and were discharged home on POD 1. Two patients (25%) did not meet discharge criteria in the PACU. The first because of an NRS = 7 that required 4 mg of IV morphine. This patient met discharge criteria the following morning and was discharged home on POD 1. The second patient had an estimated blood loss of 2400 mL (Table 1), and was discharged home on POD 2.
For all patients, pain was well controlled with <5 mg of IV morphine (Fig. 1, Table 3). Postoperative oral opioid requirements and sleep disturbances were minimal (Table 3). All patients reached at least 50% of the surgeon-defined range-of-motion goals (Table 3). All subjects underwent successful perineural infusion at home until their catheters were inadvertently dislodged (n = 1, POD 4) or removed (n = 6, POD 6).
Ambulatory Phase There were no pump malfunctions or alarms and caretakers for patients in both groups reported no difficulty removing catheters at home.
For the patients of this pilot study who underwent TSA and ambulatory perineural local anesthetic infusion, postoperative pain was well controlled with baseline and breakthrough pain intensity below levels previously reported for much smaller ambulatory orthopedic procedures (16). Patients also achieved >50% of the surgeon-defined maximal elevation and external rotation without exception, and often reached 100% of this goal. This degree of comfort and shoulder mobility was achieved with minimal oral opioid requirements and sleep disturbances, leading to a very high rate of patient satisfaction. Although this evidence demonstrates that TSA may be performed in the ambulatory environment, it does not define the appropriate subset of patients and incidence of complications associated with this practice (e.g., local anesthetic toxicity or infection). Additional research is required to define the appropriate subset of patients and determine the complication incidence associated with this practice before its mainstream use. The authors gratefully acknowledge the invaluable assistance of the staff of both the Regional Anesthesia Block Room and General Clinical Research Center, including Doug Theriaque, MS, for figure compilation.
Manufacturers donated the portable infusion pumps (Smiths Medical, St. Paul, MN) and catheters (Arrow International, Reading, PA) used for this investigation. Funding for this project provided by the University of Florida Department of Anesthesiology, Arrow International, and Smiths Medical. These two companies had no input into any aspect of study design; data collection, analysis, and interpretation; or manuscript preparation. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of these entities. Supported in part by General Clinical Research Center Grant M01-RR00082 and National Institutes of Medicine, National Institute of General Medical Sciences (Grant K23-GM077026). Supported in part by General Clinical Research Center Grant M01-RR00082 and National Institutes of Medicine, National Institute of General Medical Sciences (Grant K23-GM077026). Some of the results of this investigation were presented at the Annual Meeting of the American Society of Regional Anesthesia and Pain Medicine, Orlando, FL, March 12, 2004; and Toronto, Canada, April 22, 2005. Accepted for publication April 25, 2005.
This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|